CliffBio
small molecule

OXTELLAR XR

OXCARBAZEPINE

Loss of exclusivityApril 2027latest FDA-listed patent expiry
CompanySupernus Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameOXTELLAR XR
Active ingredientOXCARBAZEPINE
Strength150MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2012
Marketing statusRX

Listed patents

PatentExpiresType
10220042April 2027use U-2501
7910131April 2027use U-2041
9119791April 2027use U-2041
11896599April 2027product
9855278April 2027product
7722898April 2027product
8821930April 2027product
8617600April 2027product
11166960April 2027product
9370525April 2027product
9351975April 2027product

More from Supernus Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

OXTELLAR XR patent cliff — loss of exclusivity April 2027 | CliffBio